AntriaBio

Investors

Press Releases

Nov 17, 2015 AntriaBio Receives Notice of Allowance on Patent Covering Microsphere Drug Delivery Platform
Sep 16, 2015 AntriaBio Announces New Product Candidate, AB301, a Weekly GLP-1 Agonist and Basal Insulin Combination, for Type 2 Diabetes
Jun 29, 2015 AntriaBio Appoints David F. Welch, Ph.D. to Its Board of Directors
Jun 8, 2015 AntriaBio Announces Promising Preclinical Results for Once-Weekly Basal Insulin AB101
May 11, 2015 AntriaBio to Present New Preclinical Data at the American Diabetes Association 75th Scientific Sessions
Jan 8, 2015 AntriaBio Announces Appointment of Dr. Hoyoung Huh as Chairman of Scientific Advisory Board and Business Development
Jan 7, 2015 AntriaBio Announces Completion of PK/PD Studies of AB101 in Two Species
Jan 5, 2015 AntriaBio Announces $7 Million Private Placement
Nov 10, 2014 AntriaBio Extinguishes $44 Million Contingent Liability
Jul 23, 2014 AntriaBio Appoints Barry Sherman, M.D. to Its Board of Directors

Show All